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Human graft versus host disease is composed of 2 
distinct clinical entities, acute graft versus host disease 
and chronic graft versus host disease, which have differ-
ent pathogenesis. Acute graft versus host disease is pro-
duced by the attack of donor immunocompetent Tor null 
lymphocytes against recipient histocompatibility anti-
gens. The null lymphocytes may attack antigens shared 
by the donor and recipient and are autocytotoxic lym-
phocytes which can produce acute graft versus host 
disease in recipients of identical twin transplants. The 
cessation of acute graft versus host disease occurs when 
suppressor lymphocytes appear in the recipient's pe-
ripheral circulation. Chronic graft versus host disease is 
produced by immunocompetent lymphocytes that differ-
entiate in the recipient. Its control is unknown. Some 
patients with chronic graft versus host disease have in 
vivo activated suppressor lymphocytes which produce a 
secondary immunoincompetence and an increased sus-
ceptibility to bacterial sepsis and death. 
Human graft versus host disease (GVHD) is the clinical 
manifestation of the graft versus host reaction (GVHR) in man. 
Classically, the graft versus host reaction occurs following the 
infusion of immunocompetent cells into a recipient who is 
incapable of rejecting them [1-3]. In animal models, GVHR can 
be produced by the injection of parental lymphoid cells into 
neonatal F 1 recipients or of immunocompetent cells into toler-
ant or immunoincompetent recipients. The cells responsible for 
GVHR are T lymphocytes which attack histocompatibility 
antigens expressed on the recipient but not donor cells. GVHD 
has 2 components: the destruction of recipient cells by cytotoxic 
donor cells and the proliferation of recipient cells in response to 
mediators released by the donor cells. 
Human GVHD was first observed in patients with primary 
immunodeficiencies following whole blood or maternal-fetal 
transfusions which usually led to the patient's death [ 4-6]. With 
the increasing use of allogenic bone marrow transplantation 
(BMT) as therapy for severe aplastic anemia, leukemia, and 
genetically determined disorders of bone marrow function, 
GVHD has had increasing clinical significance [7-9]. GVHD 
and its sequellae are a major cause of morbidity and mortality 
in BMT, and consequently its pathogenesis and treatment are 
of great interest to centers actively engaged in BMT. 
Human GVHD has been assumed to be analogous to murine 
GVHD, i.e., GVHD is the result of the attack by donor immu-
nocompetent T cells against recipient histocompatibility anti-
gens not expressed on donor cells. Human GVHD can present 
as either or both of 2 clinical syndromes, acute GVHD and 
This work was supported by United States Public Health Science 
Grants FR-128, RR-888, Al-05877, and CA-13472. 
Reprint requests to: Robertson Parkman, M.D., Sidney Farber Can-
cer Institute, 44 Binney Street, Boston, MA 0211.5. 
Abbreviations: 
BMT: bone marrow transplant 
BSA: bovine serum 
FACS: fluorescent activated cell sorter 
GVHD: graft versus host disease 
GVHR: graft versus host reaction 
chronic GVHD, which have been assumed to be different man-
ifestations of the same underlying disease [10]. Newer infor-
mation, however, has suggested that acute GVHD and chronic 
GVHD are distinct clinical entities, each with a different path-
ogenesis (Table I). Acute GVHD is seen in greater than 75% of 
recipients of allogeneic BMT and causes death in individu~s 
with primary immunodeficiencies who receive viable allogeneiC 
lymphocytes. Acute GVHD is characterized clinically by dys-
function of the skin, liver, and gastrointestinal tract. The most 
frequent clinical manifestation is an erythematous maculopap-
ular skin rash that may first appear behind the ears. In more 
severe cases, generalized erythoderma with bullus formation 
can occur. Liver involvement is manifested by hepatocellular 
damage with elevation of hepatocellular enzymes and a second-
ary increase in bilirubin and alkaline phosphatase. Acute 
GVHD of the gastrointestinal tract presents as diarrhea with 
stool outputs as high as 5-8 liters daily. Microscopically, lym-
phocytes can be seen in biopsies of skin and liver supporting 
the contention that acute GVHD is a lymphocyte mediated 
disorder. Since biopsies of liver and gastrointestinal tract are 
infrequently obtained, most of the information available con-
cerning acute GVHD is derived from skin biopsies. Lympho-
cytes, presumably of donor origin, are found at the dermal-
epidermal junction with necrosis of single epidernal cells and 
migration of the lymphocytes into the dermis. Epithelial cells 
display other signs of cell damage including basal cell vacuol-
ization and dyskeratosis [11,12]. 
Chronic GVHD has been seen only after allogenic BMT and 
has not been seen following acute GVHD in patients with 
primary immunodeficiency who survive. The skin lesions of 
chronic GVHD are sclerodermatous with secondary limitation 
of joint motion [10,13]. Elevation of bilirubin and alkaline 
phosphatase occur without equivalent elevation of hepatocel-
lular enzymes. The GI involvement of chronic GVHD consists 
primarily of malabsorption and failure to thrive with minimal 
diarrhea. Microscopically, lymphocytic infiltrates are not seen; 
IgM and C3 deposition at the dermal-epidermal junction have 
been rep9rted [14]. The principle microscopic features are the 
deposition of dense collagen and the loss of cellular architecture. 
The presence of activated lymphocytes in the skin biopsies 
of patients with acute GVHD has suggested that acute GVHD 
might be investigated in vitro. Studies have been performed at 
the Children's Hospital Medical Center and in Seattle to eval-
uate the in vitro reactivity of circulating recipient lymphocytes 
to donor and recipient skin fibroblasts. The Seattle group 
studied the inhibition of fibroblast growth by recipient lympho-
cytes [15]. No correlation was found between the capacity of 
recipient lymphocytes to inhibit fibroblast growth and the 
presence of acute or chronic GVHD. The presence of single cell 
necrosis in skin biopsies suggests that cell death rather than 
inhibition of cell growth may be an important component of 
acute GVHD. We have investigated the capacity of recipient 
lymphocytes in vitro to lyse donor, recipient, and control fibro-
blasts. Fibroblasts were obtained from skin biopsies prior to 
transplantation and were prelabeled with 14C amino acids. After 
the incubation of patient and donor lymphocytes with target 
fibroblasts for 24 hr, the residual fibroblasts are collected on a 
MASH, and the residual radioactivity determined [16]. The 
percent cytotoxicity equals 100% residual radioactivity. Cyto-
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toxicity of greater than 20% is considered to be significant. 
Patients undergoing syngeneic and allogeneic bone marrow 
transplants have been followed longitudinally. The need for 
adequate mononuclear cells to perform the assay has prohibited 
patients from being studied when their peripheral white blood 
cell counts are less than 500/ mm3, i.e., until Day 15-20 after 
transplantation. Table II shows the results of a representative 
assay. Donor lymphocytes produced no significant lysis of pa-
tient, donor, or control fibroblasts when compared to medium 
controls. Patient lymphocytes significantly lysed recipient, con-
trol, and, in some cases, donor fibroblasts. To characterize the 
cells responsible for the cytolysis, selective removal of T lym-
phocytes by E rosette formation was performed. The E rosette 
depleted cells were more cytolytic than the unfractionated cells, 
demonstrating that the cell responsible for the fibroblast lysis 
was not aT lymphocyte. Passage of GVHD cells through nylon-
wool or cotton to remove B lymphocytes and/or monocytes 
produced no decrease in cytotoxicity. Rosette formation with 
EAC3 cells removed the cytolytic capacity of the lymphocytes 
demonstrating that the cell responsible for the fibroblast lysis 
had a C3 receptor. These observations suggest that the cell 
responsible for the in vitro fibroblast lysis associated with 
GVHD is not T but a null lymphocyte and that the target 
antigens are expressed on both donor and recipient cells. Frac-
tionation of donor and recipient cells on discontinuous gradients 
of bovine serum (BSA) has isolated a medium density popula-
tion of cells (Fraction 2) which he.s the capacity to lyse spon-
taneously both donor and recipient fibroblasts (Table III). In 
the case of the donor, there is no prior antigenic exposure to 
TABLE I. Comparison of acute and chronic graft versus host disease 
Onset 
Skin 
Liver 
Gastrointestinal 
tract 
Age dependence 
Acute 
7-21 Days post-trans-
plant 
Erythematous maculo-
papular rash 
Hepatocellular damage 
Diarrhea 
Age independent 
Chronic 
2-6 mo post-transplant 
Scleradermatous 
changes 
Obstructive hepatitis 
Malabsorption; failure 
to thrive 
Increasing frequency 
with increasing age 
TABLE II. Fibroblast cytotoxicity of lymphocytes from patient with 
acute GVHD 
Target fibroblasts % cytotoxicity 
Lymphocyte 
Recipient Donor Control 
Donor -4 0 -15 
Recipient 24 35 17 
Recipient, E-depleted 45 46 41 
Cytotoxicity of greater than 20% as compared to medium controls 
considered significant. 
TABLE Ill. Fibroblast cytotoxicity of lymphocytes from patient 
and donor 
Tm·get fibroblast % cytotoxicity 
Lymphocyte 
Recipient Donor 
Recipient 
U nfractionated 0.9 1.3 
Fraction 1 0.6 4.2 
Fraction 2 24.1 28.6 
Fraction 3 17.0 18.7 
Donor 
U nfractionated 4.0 -6.7 
Fraction 1 4.3 11.5 
Fraction 2 45.2 61.8 
Fraction 3 28.4 33.8 
Lymphocytes fractionated on BSA gradients [16] and isolated over-
night at a 100:1 ratio with radioactively labeled fibroblasts. 
Cytotoxicity of greater than 20% considered significant. 
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recipient antigens and, therefore, the reactivity is not induced 
but is spontaneous. The donor cells are autocytotoxic, i.e., they 
have the capacity to recognize and lyse self-antigens without 
prior stimulation. Autocytotoxic cells can be detected in ap-
proximately half of normal individuals [16]. Analogous experi-
ments in mice have demonstrated that autocytotoxic cells can 
be isolated from the murine spleen by BSA gradient fractiona-
tion [17]. Lymphocytes that suppress or "regulate" the auto-
cytotoxicity cells can be isolated from the BSA gradient. The 
addition of the suppressor cells to autocytotoxic cells in vitro 
inhibits autologous fibroblast lysis. The autocytotoxic cell is a 
null cell while the suppressor cell is a T lymphocyte. Thus, 
studies in normal humans and mice have demonstrated that 
autocytotoxic cells naturally occu1· and that their reactivity is 
normally regulated by suppressor T lymphocytes. The reactiv-
ity of the autocytotoxic cells can usually only be demonstrated 
after the removal of the suppressor cells. However, since auto-
reactivity is readily detected in unfractionated lymphocytes 
from patients with acute GVHD, they may be deficient in 
suppressor cells. Experiments with lymphocytes fTom patients 
with chronic GVHD have revealed no lysis of donor or recipient 
fibroblasts by circulating mononuclear cells. 
If the effector cell in some cases of acute GVHD is an 
autocytotoxic cell, which would recognize antigens shared by 
the donor and recipient, it should be expected that GVHD 
might occur in recipients of syngeneic (identical twin) BMT. 
Analysis of individuals transplanted for leukemia after prepa-
ration with total body irradiation (800-1000 R) and cyclophos-
phamide has revealed the presence of clinical and microscopic 
findings identical to those seen in the recipients of allogenec 
BMT [18]. Clinically, the patients have developed erythema-
tous maculopapular skin rashes 7 to 18 days following trans-
plantation. Skin biopsies of lesions have shown lymphocytic 
infiltration of the dermal-epidermal junction, loss of polarity of 
epidermal cells, vacuolization of the dermal-epidermal junction, 
and focal dyskeratosis. Thus, these recipients of syngeneic BMT 
have had clinical and microscopic GVHD. A previous report by 
the Seattle group comparing skin biopsies from individuals with 
allogeneic and syngeneic or autologous BMT observed that 
histopathological skin findings in both groups of patients were 
similar; however, it was thought that no GVHD could occur in 
syngeneic BMT [12]. 
Skin rashes, which have been ascribed to drug reaction, 
observed in oncology patients receiving pulse high dose chemo-
therapy, may be in reality an attack of the patients unregulated 
autocytotoxic cells against the skin after the suppressor cells 
have been selectively eliminated by the pulse chemotherapy. 
The skin biopsies of patients receiving chemotherapy were 
identical to those of recipients of autologous and syngeneic 
BMT in the Seattle study [12]. Recent reports have demon-
strated that the treatment of mice with cyclophosphamide 
selectively removes suppressor cells and that spleen cells from 
cyclophosphamide treated animals are capable of producing 
GVHD in syngeneic animals [19]. Fwther, spleen cells from 
older animals are capable of producing syngeneic GVHD with-
out cyclophosphamide treatment [20]. Thus, the clinical and 
histopathological featmes of GVHD may be produced by the 
pulse administration of chemotherapy, the infusion of autolo-
gous or syngeneic bone marrow into irradiated recipients or the 
transplantation of allogeneic bone marrow. What is common to 
all these clinical settings is the manipulation of the patient's 
immune system to produce a deficiency in the suppressor cells 
possibly necessary for regulating the effector cells producing 
GVHD. Of interest is that no clinical or histopathological 
evidence of acute GVHD is seen in recipients of identical twin 
transplants for severe aplastic anemia. However, such recipients 
do not receive any cytotoxic drugs or irradiation prior to trans-
plantation, and, therefore, their capacity to produce suppressor 
cells is unaltered. 
Suppressor cells can be quantitated either phenotypically by 
use of specific antibodies and a fluorescent activated cell sorter 
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(F ACS) or functionally following activation with con can avalin 
A (Con A). T h e suppressor cell status of patients with acute 
GVHD has been characterized using phenotypic and functional 
assays. The F ACS analysis of th e peripheral lymphocytes from 
patients with acute GVHD h as demonstrated no cells with a 
suppressor phenotype (THz+ positive) [21]. Longitudinal a nal-
ysis of acute GVHD patients has revealed t hat the cessation of 
acute GVHD coincides with appearance of lymphocytes with a 
suppressor phenotype. Functional assays of the recipient's lym-
phocytes h as established that Con A activated suppressor cells 
appear at the same time as cells with a TH2+ phenotype. Thus, 
there is a correlation between the appearance of phenotypic 
and functional suppressor T lymphocytes and t h e cessation of 
acute GVHD. This correlation has occurred in recipients of 
both allogeneic and syngeneic BMT. 
When the suppressor lymphocytes fro m 6 patients with 
chronic GVHD were assayed, a heterogeneous pattern was 
observed. Two patients had no THz + cells, 2 had normal num-
bers of TH2+ cells, and 2 had increased numbers of TH2+ cells 
that were activated in vivo as determined by th e expression of 
IA antigens. Assays for the fu nctional suppr essor capacity of 
these cells, h owever, reveals that only one patient h ad normal 
suppression after Con A activation. Two of th e patients with 
chronic GVHD were severely immunosuppressed wit h mark-
edly reduced T cell blastogenesis and agamma-globulinanemia 
a nd recently died of overwhelming bacterial sepsis, the chief 
cause of death in individuals with chronic GVHD. The patients 
who died were th ose with increased numbers of TH2 + activated 
in vivo. In co-culture experiments with normal donor lympho-
cytes, the activated TH2 + suppressor cells were capable of 
suppressing donor T cell blastogenesis. After FACS fractiona-
tion, normal immunocompetence of TH2- cells could be de-
tected [21]. Therefore, individuals -wit h chronic GVHD and 
increased numbers of activated suppressor cells h ave normal 
functioning T lymphocytes and th eir immunoincompetence is 
secondary to the activation of th eir suppressor cells. The mor-
tality of patients with chronic GVHD a nd their susceptibility 
to overwhelming bacterial sepsis is due to th eir decreased 
capacity to produce specific antibodies secondary to their acti-
vated suppressor cells. 
CONCLUSION 
Based upon these laboratory and clinical observations, our 
present conclusions con cerning human graft versus host disease 
are: 
1. Acute GVHD is ca~sed by immunocompetent cells that 
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have differentiated in t h e donor and are either T or null 
lymph ocytes. 
2. Acute GVHD h as its onset when the short-lived suppressor 
cells that are transfused with t he effector cells decrease to a 
level at which th e effector cells become cytotoxic (F igure) . 
3. Acute GVHD ceases wh en suppressor cells derived from 
the engrafted lymphoid stem cells appear. 
4. Chronic GVHD is produced by immunocompetent cells 
t hat differentiate in t he r ecipient. The control of chronic GVHD 
does not reside in th e suppressor cells that control acute GVHD. 
5. The in vivo activation of suppressor cells in patients with 
chronic GVHD produces a secondary immunoincompetence 
which is the basis of th eir increased s usceptibili ty to bacterial 
sepsis and death. 
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DISCUSSION 
SHEVACH: Would you consider treating acute gr aft-versus-
host disease with TH+ 2 donor cells or ConA activated donor 
cells? 
PARKMAN: Acute GVH disease is usually a self-limited dis-
ease and for reasons that are not clear in most transplantation 
centers, the mortality of acute GVH has nignificantly decreased 
in recent years. Obviously, if it were a greater problem one 
would entertain ideas like lymphocyte infusions. Om thoughts 
have centered on approaches that would increase the rapidity 
of the re-emergence of the suppressor cells such as giving 
thymic hormones etc ., rather than giving exogenous sources of 
lymphocytes. 
PROVOST: Have you had an opportunity to examine your 
graft-vs-host patients (both chronic and acute) for the presence 
of autoantibodies? 
PARKMAN: The UCLA group has just reported their findings 
in the American Journal of Medicine. We have found ITP 
frequently, approximately 60 days after transplantation, so I 
think that there are clones of B cells capable of producing 
autoantibodies that pass through a stage when their normal 
regulations do not occm . 
PROVOST: Dr. Evan Farmer and I have had the opportunity 
to examine the sera of a group of chronic g:raft-vs-host patients 
who have displayed IgM and/or C3 granular deposition along 
the dermal epidermal junction in a pattern similar to that seen 
in the normal skin of systemic lupus erythematosus patients. 
Previous work in Gilliam's and our laboratory have indicated 
the positive lupus band test corresponds with the presence of 
anti-native and/or single-stranded DNA antibodies. All graft-
vs-host patients demonstrating IgM and/or C3 deposition at 
the dermal epidermal junction possessed significant quantit ies 
of anti-SSDNA antibodies (Farr technique) . No anti-native 
DNA antibodies were detected (Crithidea Lucillae). 
BYSTRYN: We made an observation several years ago that 
may explain why skin is a shock organ in GVHR in terms of 
yom concepts. It is known that skin is a highly antigenic organ 
which has several families of epidermal-specifi c antigens. Of 
these, the most interesting are the antigens located in the 
cytoplasm of keratinocytes. We have found that low levels of 
antibodies to these antigens occur in about 20% of normal 
persons, indicating that the antigens often induce autoimmune 
responses. Furthermore, it has been shown that the incidence 
of these antibodies is already increased in GVHR. Thus, skin 
may be the shock organ in GVHR because there is a usually 
high incidence of latent auto-sensitivity to it, which is released 
when suppressor cells are lost following bone marrow grafts. 
BYERS: What is the specificity of the effector cell? Does it 
correlate with cytotoxicity of lymphocytes from fibroblast do-
nors? 
PARKMAN: If you remove (by absorption) the reactivity with 
autologous fibroblasts you remove the activity to MHR iden-
tical fibroblasts but not to allogeneic fibroblasts; therefore there 
are a series of cells with reactivity to fibroblas ts some of which 
are restricted to autoantigens and none to alloantigens. When 
you remove the activity to autoantigens, which are shared by 
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sibling donors, the reactivity to alloantigens is not removed. 
BYERS: Does the specificity have anything to do with for, 
example, C type viruses? Herberman showed that you could 
induce null cells by injection of C type viruses and I thought 
the reaction of identical twin lymphocytes in a leukemic twin 
might have such a specificity. 
PARKMAN: I think that one cannot exclude a possibility like 
that. 
PINCUS: In terms of the pathophysiology of chronic GVH, 
have you examined collagen synthesis and/ or fibroblast prolif-
eration? 
PARKMAN: No. 
ScHILTZ: In the autocytotoxicity experin1ents, must the effec-
tor T-cell contact the fibroblast to cause killing? If so, can 
active supernatants be generated from the interaction? 
PARKMAN: We have not done it with supernatants so om 
assumption is that one does need contact. 
ScHILTZ: Have you employed other assays for cytotoxicity? 
PARKMAN: We are now doing a chromium release assay and 
get the same sort of results. 
GoLDYNE: What is the derivation of autocytotoxic cell? 
PARKMAN: It is a null cell-non-T, Non-B cell that has, in the 
human, a C3 and and Fe receptor, and in the mou e has an Fe 
receptor. We have made aggressive attempts to remove adher-
ent cells and do not decrease reactivity; it is, therefore, not a 
monocyte/macrophage. 
GREEN: In the mouse autocytotoxic reaction could fetal calf 
serum be a factor as was the ca e of the experiments of M. 
Feldman and I. Cohen? 
PARKMAN: The assay is done in fetal calf serum. However, 
most of other experiments show that you need between 4 and 
5 days for the effector cells to become sensitized to fetal calf 
serum. We performed our assays in1mediately on the .BSA 
gradient cells. 
STREILEIN: Given that GVH reactions severely perturb the 
system of immuno-regulation, what do you feel is the primary 
initiating event in graft-versus-host disease? 
PARKMAN: First of all, I t hink it is very in1portant to say that 
GVH is not a single disease; acute GVH disease and chronic 
GVH are 2 separate diseases. I think acute GVH disease is due 
to the imbalances between effectors and suppressors that occw· 
after transplantation of cells t hat have differentiated in the 
donor, and that the in1balances that occur passively produce 
the disease. I think that the regulator (suppressor) cells are 
extremely short lived. We assume they have no capacity for 
self-replication and therefore in the recipient they die off very 
very rapidly. 
CALMAN: If you can see acute GVHD occasionally in synge-
neic BM transplants, then why don't you see GVHD in synge-
neic transfers of spleen or BM irradiated recipients in animals? 
PARKMAN: If one were to use older animals, mice that were 
a year to l Yz years old, one would find positive results. For 
instance we did experiments in which we took layer 2B cells 
and injected them into animals that were 8 or 12 weeks old. We 
could not produce any clinical disease. If, however, we took 
animals and pretreated them with either low dose total body 
irradiation or cyclophosphamide to selectively eliminate sup-
pressor cells, we were able then to produce a syngeneic GVH 
disease in non-neonatal animals. 
